|
|
|
|
|
|
|
||
© The Rockefeller University Press,
0021-9525/2000//1309 $5.00
The Journal of Cell Biology, Volume 149, Number 6,
, 2000 1309-1323
Original Article |
Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3
sjweiss{at}umich.edu
During tissue-invasive events, migrating cells penetrate type I collagen-rich interstitial tissues by mobilizing undefined proteolytic enzymes. To screen for members of the matrix metalloproteinase (MMP) family that mediate collagen-invasive activity, an in vitro model system was developed wherein MDCK cells were stably transfected to overexpress each of ten different MMPs that have been linked to matrix remodeling states. MDCK cells were then stimulated with scatter factor/hepatocyte growth factor (SF/HGF) to initiate invasion and tubulogenesis atop either type I collagen or interstitial stroma to determine the ability of MMPs to accelerate, modify, or disrupt morphogenic responses. Neither secreted collagenases (MMP-1 and MMP-13), gelatinases (gelatinase A or B), stromelysins (MMP-3 and MMP-11), or matrilysin (MMP-7) affected SF/HGF-induced responses. By contrast, the membrane-anchored metalloproteinases, membrane-type 1 MMP, membrane-type 2 MMP, and membrane-type 3 MMP (MT1-, MT2-, and MT3-MMP) each modified the morphogenic program. Of the three MT-MMPs tested, only MT1-MMP and MT2-MMP were able to directly confer invasion-incompetent cells with the ability to penetrate type I collagen matrices. MT-MMP–dependent invasion proceeded independently of proMMP-2 activation, but required the enzymes to be membrane-anchored to the cell surface. These findings demonstrate that MT-MMP–expressing cells can penetrate and remodel type I collagen-rich tissues by using membrane-anchored metalloproteinases as pericellular collagenases.
Key Words: collagen • metalloproteinases • scatter factor/hepatocyte growth factor • mock • tubulogenesis
© 2000 The Rockefeller University Press
 |
Introduction |
|---|
 TopAbstract Introduction Materials and MethodsResultsDiscussionReferences |
|---|
Beyond the identification of the specific MMPs that promote collagen degradation, additional constraints complicate our ability to understand the manner in which these systems are mobilized during invasive processes. First, MMPs are uniformly synthesized as inactive zymogens with latency maintained by the enzymes' prodomains. Hence, the expression of degradative activity usually requires a bimolecular proteolytic processing event wherein the MMP prodomain is removed (Nagase and Woessner 1999). Secondly, the invading cell must either position the type I collagenase activity on its surface in a manner that allows tissue-invasive signals to be interpreted accurately or induce collagenolytic activity in surrounding cell populations in a spatially regulated manner (Werb 1997; Murphy and Gavrilovic 1999). Thirdly, both the processing of the MMP zymogen to its mature form and the retention of the enzyme's collagenolytic activity must take place in tissues that are normally bathed in high concentrations of circulating antiproteinases (Weiss 1989).
Whereas solitary cells can display invasive phenotypes, branching morphogenesis requires cells to invade and remodel the surrounding collagen matrix in a coordinated fashion to ultimately establish a defined structure (Gumbiner 1992; Birchmeier and Birchmeier 1993). As collagen-degrading MMPs would be predicted to either enhance or modify such tubulogenic programs, we reasoned that an in vitro model that recapitulates a morphogenic process would provide a sensitive platform for identifying the subset of proteinases that participate in the remodeling of the type I collagen matrix. MDCK cells are highly differentiated epithelial cells that can be induced to undergo branching morphogenesis in type I collagen matrices in response to the morphogen, scatter factor/hepatocyte growth factor (SF/HGF; Montesano et al. 1991a,Montesano et al. 1991b, Montesano et al. 1999). As such, we stably transfected MDCK cells to overexpress each of ten different MMPs that previously have been linked to invasive/morphogenic states (Nagase and Woessner 1999), and examined the ability of these cells to interpret proinvasive, as well as tubulogenic signals. Surprisingly, seven of the ten secreted MMPs tested, which included the type I collagenases: MMP-1 (collagenase 1), MMP-13 (collagenase 3), and MMP-2 (gelatinase A), failed to modulate invasion or morphogenic responses. However, three MMPs were identified that either accelerated, disrupted, or modified branching tubulogenesis. Interestingly, this subset of proteinases all belong to the membrane-anchored family of MMPs (i.e., the membrane-type MMPs [MT-MMPs]; Murphy and Gavrilovic 1999; Nagase and Woessner 1999). The ability of membrane-anchored, rather than secreted, MMPs to regulate the SF/HGF-dependent tubulogenic program suggests that this class of enzymes has been specifically engineered to mediate pericellular proteolytic processes associated with cell invasion and morphogenesis through type I collagen-rich barriers.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Expression Vector Construction and Transfection
Full-length cDNAs were generated using the following primer sets: MT1-MMP, forward TCT CGG ACC ATG TCT CCC GCC CCA, reverse CTA TCA GAC CTT GTC CAG CAG GGA; MT2-MMP, forward GGG CGC CGA GAG CAT GGG CAG; reverse CTA TCA GAC CCA CTC CTG CAG CGA; MT3-MMP, forward GCA CAG TTC ACT ATG ATC TTA CTC, reverse CTA CTA CAC CCA CTC TTG CAT AGA; MMP-9 (gelatinase B), forward CTC ACC ATG AGC CTC TGG CAG CCC, reverse TAG TCC TCA GGG CAC TGC AGG ATG; MMP-2 (gelatinase A), forward GGG AGC GCT ACG ATG GAG GCG CTA, reverse CCA GGG CCA GCT CAG CAG CCT AGC; MMP-3 (stromelysin-1), forward GTA AAG CCA GTG GAA ATG AAG AGT, reverse CTA TCA ACA ATT AAG CCA GCT GTT. The resulting full-length PCR products were cloned into pCR3.1 Uni vector (Invitrogen) according to the manufacturer's instructions. Full-length MMP-1 (collagenase-1) cDNA was obtained by assembling a 5' PCR fragment (using a primer set consisting of: forward, GGA AGC TTA CCT TGC ACT GAG AAA G, reverse TCC AAT ACC TGG GCC TGG T) and an XbaI fragment containing the 3' end of human MMP-1 isolated from p35-1 (ATCC). Full-length human MMP-13 (collagenase-3; provided by Peter Mitchell, Pfizer, Groton, CT) was subcloned as a HindIII fragment in pCR3.1 Uni. Full-length human MMP-7 (matrilysin) cDNA was provided by Lynn Matrisian (Vanderbilt University, Nashville, TN) and subcloned in pCR3.1 Uni as an EcoRI fragment. Full-length MMP-11 cDNA (Pei et al. 1994) was subcloned into the HindIII/XbaI sites of pCR 3.1 Uni from pREP9. Soluble MT1-MMP (
MT1-MMP; Met1-Gly535), which lacks the COOH-terminal transmembrane and cytosolic domains of the wild-type proteinase, and a cytosolic tail-truncated mutant MT1-MMP (MT1-MMPct; Met to Phe563) were generated as described (Ohuchi et al. 1997; Hiraoka et al. 1998). To generate soluble MT2-MMP (MT2-MMP; Met1-Asn625), a BstEII–XhoI fragment was excised from a full-length MT2-MMP expression plasmid and replaced with a PCR fragment synthesized using a primer set consisting of: forward, TGT CTT TTT CAA AGG TGA CCG CTA CTG GCT CT, reverse, AGA CTC GAG CGG CCA ATT TCA GTT CAC CGT CCG TGC CAC CTC CTC CA. Epitope-tagged MT1-, MT2-, and MT3-MMP constructs were generated by inserting primers encoding the FLAG epitope (5'-GAC TAC AAG GAC GAC GAT GAC AAG-3') after the COOH-terminal valine of each molecule and cloned into pCR3.1 Uni.
Stably transfected MDCK cell lines were generated using lipofectamine (Life Technologies) according to the manufacturer's instructions. After transfection, single colonies were isolated after 2–3 wk of G418 selection. For stable transfectants, results shown are representative of three or more clones tested. COS-1 cells were transiently transfected using lipofectamine in the same manner, but without G418 selection.
Cell Proliferation, Scattering, and Migration Assays
To measure cell proliferation rates, 5 x 104 cells were plated into each well of a 12-well tissue culture plate (Costar, Corning Inc.) and cultured for 3, 5, or 7 d in complete medium as described above. At each time point, the cells were harvested by trypsinization and counted using a hemacytometer. Cell scattering was assessed by seeding 2 x 105 cells/well in 6-well tissue culture plates (Costar, Corning Inc.). After 18–24 h, the culture medium was replaced with fresh culture medium either alone or containing 50 ng/ml SF/HGF (Genentech, Inc.). After an additional 24 h, the cultures were examined using phase-contrast optics and photographed. Cell migration rates were assessed by seeding 2–5 x 105 cells atop collagen gels with surfaces partially covered by glass coverslips (1 x 2 mm; Corning Inc.). When the cells reached confluence, the glass fragments were removed, leaving a well-demarcated, cell-free area on the gel. At this time, SF/HGF (50 ng/ml) was added to all cultures in the absence or presence of the synthetic MMP inhibitor, BB-94 (5 µM; gift of British Biotechnology) and the distances migrated across the gels were measured 24 h later using an ocular micrometer on a Nikon inverted microscope.
Invasion and Tubulogenesis Assays
Collagen.
Type I collagen was prepared from rat tail tendons as described (Elsdale and Bard 1972) and dissolved in 0.2% acetic acid to a final concentration of 2.7 mg/ml. To induce gelling, collagen was mixed with 10x DME and 0.34 N NaOH in an 8:1:1 ratio at 4°C, and 1 ml of this mixture was added to the upper well of a 24-mm Transwell dish (3-µm pore size; Corning, Inc.). After gelling was complete (45 min at 37°C), 2–5 x 105 cells in complete medium were added to the upper well. After an additional 24-h incubation period, SF/HGF was added to the lower compartment of the Transwell chambers at a final concentration of 50 ng/ml. In indicated experiments, protease inhibitors were added to both the upper and lower wells at the following final concentrations: 5 µM BB-94 (0.1% DMSO; final concentration); 200 ng/ml recombinant tissue inhibitor of metalloproteinase-1 (TIMP-1; Oncogene Research Products); 200 ng/ml recombinant TIMP-2 (gift of Amgen, Thousand Oaks, CA); 200 µg/ml aprotinin; 10 µM bestatin; 100 µg/ml soybean trypsin inhibitor (SBTI); 100 µM E64 (0.1% ethanol; final concentration); and 50 µM pepstatin (0.1% methanol; final concentration; all from Sigma-Aldrich). None of the solvents used affected MDCK or COS-1 cell behavior when tested alone. FCS was depleted of plasminogen or gelatinase, respectively, by lysine-sepharose or gelatin-sepharose (both from Amersham Pharmacia Biotech) affinity chromatography (Rosenthal et al. 1998). All media, including SF/HGF and inhibitors, were replaced every 2 d. MDCK and COS-1 invasion assays were routinely terminated after 12 and 5 d, respectively. Invasive foci were counted in randomly selected fields at 20x on a phase-contrast microscope. Invasion depths were measured from digitally captured images of hematoxylin and eosin-stained cross-sections.
Matrigel.
Cell invasion into a reconstituted basement membrane extract was assessed by adding 800 µl of Matrigel (Becton Dickinson) to the upper well of 24-mm Transwell dishes. After gelling at 37°C for 30 min, 2–5 x 105 cells were added to the upper compartment. After a 24-h incubation period, the medium was exchanged and SF/HGF (50 ng/ml) was added to the lower chamber. Media and SF/HGF were replaced every 2 d in the course of a 12-d incubation period.
Peritoneum.
Peritoneum-derived cultures were prepared by gently stretching fat-free portions of rat gut mesentery (resected from adult male rats anesthetized and then killed) over the opening of a 12-mm Transwell from which the polycarbonate membrane had been removed. The mesentery was tied onto the well with surgical silk thread, and the outer edge of the mesentery below the thread was cut away with a scalpel. Mesothelial cells were lysed by immersion in 1 N ammonium hydroxide for 1 h at room temperature. The wells were then rinsed repeatedly in culture medium and placed inverted in a 15-cm petri dish. A small bolus of type I collagen (
100 µl) was applied to the bottom of the peritoneum and was gelled for 45 min at 37°C. After gelling, the wells were inverted and placed in clean 12-well dishes and 1–2 x 105 cells were added to the upper wells onto the surface of the peritoneum in complete medium. After 24 h, the medium was exchanged and SF/HGF (50 ng/ml) was added to the lower compartments in the absence or presence of BB-94 as described above.
Western Blots and Zymography
MMP protein expression by stably transfected clones was assessed by Western blotting as described (Pei and Weiss 1995, Pei and Weiss 1996), with the exception of MT3-MMP (see below). For secreted MMPs (MMP-1, -2, -3, -7, -9, -11, and -13), as well as soluble MT1-MMP and MT2-MMP, MDCK clones were incubated for 24 h in serum-free medium and supernatants were collected in the presence of proteinase inhibitor cocktail (Calbiochem). MT-MMP proteins were solubilized from Triton X-114–extracted cells as described by Toth et al. 1997. Supernatants and detergent extracts were resolved by PAGE under reducing conditions and the proteins transferred to nitrocellulose membranes. Immunoblot analyses were performed with one of the following antibodies: MMP-1 rabbit polyclonal (gift of H. Birkedal-Hansen, National Institute of Dental and Craniofacial Research, Bethesda, MD) at 1:2,000; MMP-2 mouse monoclonal (Molecular Oncology, Inc.) at 1:2,000; MMP-3 mouse monoclonal (Calbiochem # IM236L) at 1:200; MMP-7 rabbit polyclonal (gift of H. Welgus, Parke-Davis, Ann Arbor, MI) at 1:500; MMP-9 rabbit polyclonal (gift of H. Welgus) at 1:5,000; MMP-11 rabbit polyclonal (Pei et al. 1994) at 1:1,000; MMP-13 rabbit polyclonal (gift of Peter Mitchell, Pfizer, Groton, CT) at 1:2,000; MT1-MMP mouse monoclonal (Calbiochem # IM39L) at 1:500; MT2-MMP mouse monoclonal (Calbiochem # IM48L) at 1:500; and mouse monoclonal M2 against a FLAG epitope (Sigma-Aldrich) at 1:1,000. After incubation with HRP-conjugated anti-mouse or anti-rabbit IgG secondary antibody, protein bands were visualized using an ECL kit according to the manufacturer's instructions (Pierce Chemical Co.).
The ability of cells to activate MMP-2 was determined by gelatin zymography (Rosenthal et al. 1998). In brief, cells were incubated with serum-free medium containing recombinant proMMP-2. After a 24-h incubation at 37°C, the supernatants were collected and resolved under nonreducing conditions on 10% polyacrylamide gels impregnated with 2 mg/ml gelatin (Sigma-Aldrich). Gels were rinsed once in 2.5% Triton X-100 for 30 min at room temperature and then incubated in developing solution (50 mM Tris-HCl, 5 mM CaCl2, 1 µM ZnCl2, pH 7.6) for 8–16 h. Gels were stained with Coomassie blue and areas of gelatinolytic activity were detected as transparent bands.
Northern Blot
As commercially available MT3-MMP antibodies lacked sensitivity (i.e., epitope-tagged MT3-MMP expressed in transiently transfected cells was detectable with antiepitope, but not anti-MT3-MMP antibodies; see below), stable clones were identified by Northern blot analysis. Total RNA was isolated from MT3-MMP–transfected and control MDCK cells using TRIzol reagent (Life Technologies) according to the manufacturer's instructions. RNA (10 µg/lane) was electrophoretically separated in a 1% agarose-formaldehyde gel, transferred to a nylon filter (Hybond-N; Amersham Pharmacia Biotech) and hybridized with 32P-labeled cDNA probes for human MT3-MMP and 36B4. Bands were visualized by autoradiography as described (Rosenthal et al. 1998).
Immunofluorescence, Light, and Electron Microscopy
E-cadherin immunofluorescence was performed as described (Lochter et al. 1997a) using a mouse monoclonal E-cadherin antibody (Transduction Laboratories; # C20820) at 1:100 and Texas red-conjugated anti-mouse IgG (Vector Laboratories, Inc.). Fluorescent images were captured using a Spot digital camera (Diagnostic Instruments, Inc.) through a Leica upright microscope.
Collagen and Matrigel cultures were prepared for light microscopy after fixation in 4% paraformaldehyde in PBS. Fixed gels were then removed from the Transwell, dehydrated in a graded ethanol series, and embedded in paraffin. Sections (5–7-µm thick) were cut and stained with hematoxylin and eosin. For electron microscopy, gels were fixed in 2% glutaraldehyde/1.5% paraformaldehyde in 0.1 M sodium cacodylate buffer, postfixed in 1% osmium tetroxide, and embedded in epoxy resin. Sections (500-nm thick) were stained with toluidine blue before examining by transmission electron microscopy (TEM) as described (Hiraoka et al. 1998). Peritoneum cultures were prepared as for TEM, and bright-field images of toluidine blue stained sections were captured digitally before TEM examination.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
|
MT1-MMP). Whereas the enhanced degradative potential of MT1-MMP transfectants was not affected by deleting the cytosolic tail of the proteinase, membrane anchoring proved essential as the tubulogenic response of the wild-type phenotype was recovered when the metalloproteinase was expressed as a soluble mutant (Fig. 4, A–D). Because the transmembrane deletion mutant is secreted as a fully active enzyme (Pei and Weiss 1996; Ohuchi et al. 1997), these results indicate that MT1-MMP must be anchored to the cell surface to affect invasion and/or branching morphogenesis.
|
MT-MMPs as Morphogenic Regulators
MT1-MMP is structurally related to at least two other membrane-anchored MMPs, MT2-MMP and MT3-MMP (Nagase and Woessner 1999). To determine whether invasion and/or branching morphogenesis could be similarly modulated by these proteinases, we isolated and examined stable MDCK clones that overexpressed either MT2-MMP or MT3-MMP alone (Fig. 5 A). As shown in Fig. 5, MT2-MMP and MT3-MMP transfectants displayed growth patterns (data not shown) and morphologic characteristics similar to control-transfected clones (Fig. 5 B). In addition, scattering responses across a plastic substratum (Fig. 5 B), as well as migratory rates across the surface of collagen gels, were unaffected (563 ± 40 µm/24 h, 533 ± 38 µm/24 h, and 575 ± 37 µm/24 h, respectively, and for control, MT2-MMP, and MT3-MMP transfectants; n = 3). Unexpectedly, however, MT2-MMP transfectants stimulated with SF/HGF lost almost all invasive and morphogenic activity in the three-dimensional collagen gel system (Fig. 5 C). Instead, MT2-MMP–overexpressing cells formed a disorganized multilayered structure atop the collagen matrix. While not frankly invasive, TEM analysis demonstrated that the SF/HGF-stimulated cells extended shallow, invasive processes into the collagen gel via a BB-94– or TIMP-2–sensitive mechanism (Fig. 5 C). Membrane anchoring of MT2-MMP was required for this effect as MDCK transfectants overexpressing soluble MT2-MMP displayed invasive and tubulogenic properties indistinguishable from control transfectants (data not shown). As epithelial cells that overexpress active MMPs have been reported to undergo an epithelial-to-mesenchymal cell transformation (Lochter et al. 1997b), the absence of a morphogenic response raised the possibility that MT2-MMP transfectants had lost their epithelial cell-like characteristics. However, MT2-MMP overexpressing cells expressed a normal tubulogenic program when triggered with SF/HGF atop thick matrices of Matrigel (Fig. 5 E).
|
MT-MMP–dependent Regulation of MDCK Invasion through Interstitial Stroma
Whereas increasing the expression of MT-MMPs in MDCK cells altered invasion and branching morphogenesis in type I collagen gels, this reconstituted matrix displays physical properties distinct from those of cross-linked collagen in vivo (Birkedal-Hansen 1987; Rosenthal et al. 1998). To determine the ability of MT-MMPs to remodel a more physiologic matrix, control or MT-MMP transfectants were cultured atop an acellular sheet of peritoneum-derived interstitial tissue (Fig. 6). This tissue consists of a network of type I collagen and elastin fibers sandwiched between two discontinuous basement membranes (Fig. 6 A, inset; Parsons et al. 1983). Significantly, SF/HGF-stimulated control MDCK cells were unable to cross this more complex barrier (Fig. 6A and Fig. D). Cells overexpressing MT1-MMP, however, vigorously invaded the peritoneal tissue after SF/HGF stimulation, forming large pits similar to those seen on type I collagen and leaving only small stretches of peritoneum intact (Fig. 6B and Fig. D). As expected, this degradative process was inhibited completely by TIMP-2 (data not shown) or BB-94 (Fig. 6C and Fig. D). An even more dramatic effect was seen with MT2-MMP transfectants, as these cells completely degraded large stretches of the tissue within three to four days of SF/HGF stimulation, eventually eliminating nearly all visible tissue via a BB-94–sensitive process (Fig. 6 E).
|
MT1-MMP and MT2-MMP Function as Membrane-anchored Invasive Factors
Whereas MT1-MMP and MT2-MMP modified the morphogenic program displayed by SF/HGF-stimulated MDCK cells, the ability of these enzymes to regulate collagen-invasive activity directly cannot be ascertained by this experimental approach, as the host cell coexpresses a complement of endogenously derived proteinases (Montesano et al. 1991a,Montesano et al. 1991b, Montesano et al. 1999). Consequently, COS-1 cells, which do not express MT-MMPs (Sato et al. 1994), were transiently transfected with MT1-, MT2-, or MT3-MMP and collagen-invasive activity monitored. As shown in Fig. 7 A, cells transfected with FLAG epitope-tagged constructs expressed each of the respective proteinases. Furthermore, though the mature forms of MT2-MMP or MT3-MMP have not yet been identified in the literature, the enzymatic activity of the proteinases was monitored indirectly as the ability of the transfected cells to process exogenously supplied progelatinase A to its mature form. Using this assay, each of the MT-MMP transfectants displayed comparable activity (Fig. 7 B). Significantly, when the MT-MMP–transfected COS-1 cells were cultured atop the type I collagen substratum, both MT1- and MT2-MMP–overexpressing cells acquired an invasive activity (Fig. 7D and Fig. E) that was inhibitable by both BB-94 and TIMP-2 (Fig. 7G and Fig. H). Invasion was completely dependent on membrane anchoring of the proteinases to the cell surface, as COS-1 cells transiently transfected with either soluble transmembrane-deleted MT1-MMP or MT2-MMP failed to express an invasive phenotype (1.0 ± 0.8 invasive foci/field and 2.0 ± 1.0, n = 3; invasive foci/field for MT1-MMP and MT2-MMP, respectively). MT3-MMP–transfected cells extended only a few short processes into the underlying collagen (Fig. 7 F) in a fashion similar to that observed in control-transfected cells (Fig. 7 C). Thus, both MT1-MMP and MT2-MMP, but not MT3-MMP, confer invasion-null cells with the ability to penetrate type I collagen matrices.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
MMP family members can potentially cleave integrins and cadherins, as well as other surface-associated molecules that can initiate a process leading to stable epithelial-to-mesenchymal conversion (Lochter et al. 1997b; Werb 1997; Sternlicht et al. 1999). Consequently, we predicted that cells overexpressing MT-MMPs would display aberrant phenotypic characteristics similar to those described previously (Lochter et al. 1997b). However, neither MT1-, 2-, nor 3-MMP affected MDCK proliferation, cell–cell interactions, or scattering responses to SF/HGF. Furthermore, all of the MT-MMP transfectants retained the ability to generate patent tubular networks in Matrigel. MT1-MMP overexpressing clones did, however, display a markedly enhanced ability to invade type I collagen matrices resulting in the formation of cyst-like structures that eventually dissolved the underlying matrix. Interestingly, the transformation of a branching tubulogenesis-like program into one more reminiscent of cyst development has been observed in collagenase-treated embryonic submandibular glands induced to undergo branching in vitro (Fukuda et al. 1988). MT1-MMP similarly disrupted the tubulogenic activity of SF/HGF-treated MDCK cells, presumably by degrading the collagen matrix at a rate permissive for invasion, but not branching.
Recent studies have suggested that MT-MMP functional activity requires its regulated trafficking to the plasma membrane via a mechanism that is partially dependent on the COOH-terminal valine found at the end of the cytosolic tails of MT1-, MT2-, and MT3-MMP (Urena et al. 1999). Furthermore, on the cell surface, MT1-MMP has been reported to concentrate into discrete zones near the invading front via additional targeting sequences embedded in the metalloproteinase's transmembrane domain and/or cytosolic tail (Nakahara et al. 1997). In this manner, MT1-MMP localized to the cell–substratum interface could mediate collagenolytic effects directly or indirectly by processing other collagenolytic enzymes to their active forms (i.e., progelatinase A or procollagenase-3; Sato et al. 1994; Knauper et al. 1996). However, in our system, the cytosolic tail-deleted mutant was not only processed to its mature form in normal fashion, but it also induced an invasive program indistinguishable from that of the wild-type enzyme. Similarly, we have also determined that a chimeric construct of MT1-MMP, wherein the wild-type transmembrane domain and tail has been replaced, also retains full invasive activity (our unpublished observation). Whereas neither the cytosolic tail nor the transmembrane domain of MT1-MMP appear to encode critical signals, membrane anchoring to the cell surface proved essential to the invasive process. When MDCK or COS-1 cells were transfected with a soluble form of the enzyme that expresses type I collagenolytic activity (D'Ortho et al. 1997; Ohuchi et al. 1997), the invasive phenotype of these MDCK clones reverted to that observed in the control transfectants. Thus, MT1-MMP only confers invasive activity when confined to the pericellular compartment where it can be concentrated at the cell–substratum interface into sequestered zones that would presumably optimize enzyme–substrate interactions, as well as restrict the access of circulating proteinase inhibitors. Membrane anchoring of MT1-MMP can also accelerate the enzyme's ability to catalyze proMMP-2 activation (Nagase and Woessner 1999), but we were unable to implicate MMP-2 in the invasion process. Whereas previous studies have suggested that MMP-2 can act as a type I collagenase (Aimes and Quigley 1995), these conclusions have recently been questioned (Seltzer and Eisen 1999).
Given the ability of MT1-MMP to modify the invasive activities of recipient cells, we predicted that similar effects might be obtained with MT2-MMP and MT3-MMP. However, despite the facts that the overall domain structures of MT2- and MT3-MMP are virtually identical to that of MT1-MMP, and the enzymes display similar abilities to activate progelatinase A (Nagase and Woessner 1999), each of the proteinases affected invasion in a manner distinct from that observed with MT1-MMP. In the case of MT2-MMP, the morphogenic program of SF/HGF-stimulated MDCK cells was completely ablated, even though the cells displayed an epithelial phenotype and scattered in response to SF/HGF. Interestingly, whereas MT2-MMP transfectants were unable to express a tubulogenic phenotype in type I collagen gels, foci of degradative activity were identified along the basilar face of SF/HGF-stimulated cells. As MT2-MMP transfectants retained normal invasive activity when stimulated atop Matrigel, we posited that MT2-MMP disrupted type I collagen invasion by degrading the underlying substratum in a discoordinated fashion that prevented the cells from establishing the adhesive interactions necessary for migration. Indeed, when MT2-MMP transfectants were cultured atop the peritoneum in an effort to present the cells with a more protease-resistant matrix, the cells not only invaded, but actually dissolved the peritoneum despite the presence of serum antiproteinases. We cannot rule out the possibility that MT2-MMP penetrated the peritoneum by degrading extracellular matrix components other than type I collagen, or that MT2-MMP interacted with an as yet unidentified MDCK-derived proteinase. However, COS-1 cells transfected with full-length, but not soluble, MT2-MMP expressed a collagen-invasive activity similar to that observed with MT1-MMP–transfected cells. Most probably, COS-1 cells regulated MT2-MMP expression and motility in a more balanced fashion than the MDCK transfectants, thus allowing invasion to proceed. Recently, D'Ortho et al. 1997 reported that soluble MT2-MMP cannot degrade type I collagen, but the membrane-anchored form of the enzyme appears to express activities distinct from those displayed by the truncated proteinase. Nonetheless, we do note that MT2-MMP was not as efficient as MT1-MMP in driving collagen invasion. Whether these differences reflect differences in the enzymes' respective substrate repertoires or the efficiency with which the metalloproteinase zymogens are processed to their active forms remains to be determined.
The ability of MT1-MMP and MT2-MMP to regulate invasive activity is consistent with recent studies demonstrating that these two proteinases are widely expressed in normal tissues, as well as a variety of carcinomatous states (e.g., Ueno et al. 1997; Polette and Birembaut 1998; Nakada et al. 1999). However, MT3-MMP expression appears to be much more restricted in both normal and neoplastic tissues (e.g., Ueno et al. 1997; Nakada et al. 1999). In contrast to MT1-MMP and MT2-MMP, MT3-MMP only subtly modified the SF/HGF-induced response by favoring a more cyst-like morphogenic program. Based on recent studies of recombinant soluble MT3-MMP (Shimada et al. 1999), this effect could be due to the ability of the proteinase to partially solubilize intact type I collagen by cleaving within the telopeptide regions that harbor interchain cross-links, degrading gelatin (i.e., denatured type I collagen) after proteolysis of type I collagen, or hydrolyzing MDCK-derived extracellular matrix molecules and generating bioactive fragments capable of altering cell function (Werb 1997). The inability of MT3-MMP to promote collagen-invasive activity should not be misconstrued to suggest that the proteinase cannot affect invasive activity through other biologically relevant matrices. Soluble MT3-MMP has been reported to degrade fibrillar type III collagen (Shimada et al. 1999) and we have also determined that MT3-MMP overexpressing MDCK cells display marked fibrin-invasive activity (our unpublished observation). Thus, we favor a scenario in which distinct MT-MMPs promote invasive and/or morphogenic responses in a manner dictated by the enzymes' proteolytic profile and the characteristics of the connective tissue barrier confronting the cell (e.g., Belien et al. 1999; Koshikawa et al. 2000).
Given the ability of MT-MMPs to affect invasive activity, it was surprising that none of the secreted MMPs that we tested altered the MDCK or COS cell phenotypes in a discernable fashion. However, three issues bear consideration. First, few in vitro or in vivo studies have directly examined the role of specific MMPs in type I collagen invasion (Benbow et al. 1999). In vitro, MMP-9 and MMP-3 are the only metalloproteinases that have been indirectly linked to cell invasion programs through type I collagen gels (Lochter et al. 1997a; Mason et al. 1999). MMP-1 has also been reported to play a required role in keratinocyte migration across type I collagen-coated surfaces in vitro, but invasion was not examined (Pulcher et al. 1997). In our studies, no effects were observed on either cell migration, invasion, or morphogenesis when any of these MMPs were overexpressed. In this regard, it is worth noting that in vivo studies with MMP-2–/–, MMP-3–/–, MMP-7–/–, and MMP-11–/– mice have demonstrated that these animals develop normally and display only subtle defects in their ability to remodel the extracellular matrix (Dunsmore et al. 1998; Itoh et al. 1998; Liu et al. 1998; Masson et al. 1998; Mudgett et al. 1998; Wang et al. 1999). MMP-9–/– mice exhibit abnormal patterns of skeletal growth plate vascularization and ossification, but interestingly, defects are temporary and primarily restricted to bone where MMP-9 acts as an angiogenic activator (Vu et al. 1998). MMP-9 has also been reported to participate in renal morphogenesis in vitro, but similar effects in knockout mice have not yet been described (Lelongt et al. 1997).
The somewhat limited effects of deleting soluble members of the MMP family stand in marked contrast to the more global and severe defects recently observed in MT1-MMP–/– mice (Holmbeck et al. 1999). In these animals, dwarfism, osteopenia, arthritis, and premature mortality have been primarily attributed to defects in type I collagen turnover. Interestingly, renal epithelial cells undergoing branching morphogenesis in vivo have been shown to transiently express MT1-MMP (Ota et al. 1998; Tanney et al. 1998). Furthermore, as MDCK cells can express low levels of MT1-MMP in vitro (Kadono et al. 1998; our unpublished observation), MT-MMPs may well participate in morphogenic programs in vivo. Specific defects in collagen-invasive or branching activity have not yet been examined in MT1-MMP–/– mice, but the multiple and severe defects that occur in these animals highlight the relative importance of membrane-anchored MMPs.
Second, despite the relative paucity of studies attempting to determine the means by which invading cells remodel type I collagen in vitro or in knockout animals, alterations in extracellular matrix structure/function have been observed in transgenic animals engineered to overexpress MMP-1, -3, or -7 (e.g., Sympson et al. 1994; Witty et al. 1995; D'Armiento et al. 1995; Rudolph-Owen et al. 1998; Sternlicht et al. 1999). However, these effects are complicated by the fact that MMPs induce epithelial-to-mesenchymal cell conversions in vivo with attendant changes in the expression profile of affected cell populations (Sternlicht et al. 1999). These types of analyses clearly underline the importance of MMPs in regulating tissue architecture and function, but the role of individual proteinases remains difficult to establish.
Finally, the above issues notwithstanding, increasing evidence suggests that the matrix remodeling events that occur coincident with invasive or morphogenic processes are most efficiently mediated by cell surface-associated proteinases. In this manner, a balance is struck between proteolysis and motility such that sufficient matrix is cleared to allow forward movement while leaving a substrate underfoot for propulsive movement (Werb 1997; Hiraoka et al. 1998; Murphy and Gavrilovic 1999). MT-MMPs may be specifically adapted for this purpose as the proteinases are activated and then tethered to the cell surface. Indeed, when either MT1- or MT2-MMP were truncated to generate secreted proteinases, all proinvasive effects were lost, despite the fact that the enzymes are efficiently processed to their active forms. Similarly, though MDCK clones overexpressing MMP-2, -3, or -11 were each able to activate a portion of the secreted metalloproteinase, no effect on invasion or tubulogenesis was observed. Thus, the inability of secreted MMPs to participate in invasive events most likely reflects their inefficient localization to the surface of MDCK or COS cells. Indeed, under appropriate conditions, even secreted proteinases may display important functional activities after membrane binding. For example, active MMP-2 can associate with the integrin 
vβ3, whereas MMP-9 can bind to cell surfaces via interactions with the 2(IV) chain of collagen or CD44 (Brooks et al. 1996; Olson et al. 1998; Yu and Stamenkovic 2000). In the latter case, a membrane-anchored, but not soluble, mutant form of MMP-9 was shown to regulate tumor invasion and angiogenesis (Yu and Stamenkovic 2000). Taken together, these data suggest that either membrane-anchored or membrane-associated proteinases are ideally positioned for regulating movement through three-dimensional structures. Given the multiple normal and neoplastic cell types known to express MT-MMPs, we posit that this class of enzymes will prove to play key roles in allowing invading cells to negotiate and remodel interstitial matrix barriers.
|
Acknowledgments |
|---|
This work was supported in part by the National Institutes of Health Grant CA71699 (to S.J. Weiss) and by Biogen, Inc.
Submitted: 15 March 2000
Revised: 1 May 2000
Accepted: 1 May 2000
Abbreviations used in the paper: MMP, matrix metalloproteinase; MT-MMP, membrane-type MMP; SBTI, soybean trypsin inhibitor; SF/HGF, scatter factor/hepatocyte growth factor; TIMP, tissue inhibitor of metalloproteinases.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Aimes R.T. & Quigley J.P.. Matrix metalloproteinase-2 is an interstitial collagenase, J. Biol. Chem., 270, 1995, 5872–5876.
Belien A.T.J., Paganetti P.A. & Schwab M.E.. Membrane-type 1 matrix metalloproteinase (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter, J. Cell Biol., 144, 1999, 373–384.
Benbow U., Schoenermark M.P., Mitchell T.I., Rutter J.L., Shimokawa K., Nagase H. & Brinckerhoff C.E.. A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen, J. Biol. Chem., 274, 1999, 25371–25378.
Birchmeier C. & Birchmeier W.. Molecular aspects of mesenchymal–epithelial interactions, Annu. Rev. Cell Biol., 9, 1993, 511–540.
Birkedal-Hansen H.. Catabolism and turnover of collagenscollagenases, Meth. Enzymol., 144, 1987, 140–167.[Medline]
Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P. & Cheresh D.A.. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin vβ3, Cell., 85, 1996, 683–693.[Medline]
D'Armiento J., Dicolandrea T., Dalal S.S., Okada Y., Huang M.-T., Conney A.H. & Chada K.. Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis, Mol. Cell. Biol., 15, 1995, 5732–5739.[Abstract]
D'Ortho M.-P., Will H., Atkinson S., Butler G., Messent A., Gavrilovic J., Smith B., Timpl R, Zardi L. & Murphy G.. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases, Eur. J. Biochem., 250, 1997, 751–757.[Medline]
Dunsmore S.E., Saarialho-kere U.K., Roby J.D., Wilson C.L., Matrisian L.M., Welgut H.G. & Parks W.C.. Matrilysin expression and function in airway epithelium, J. Clin. Invest., 102, 1998, 1321–1331.[Medline]
Elsdale T. & Bard J.. Collagen substrata for studies on cell behavior, J. Cell Biol., 54, 1972, 626–637.
Fukuda Y., Masuda Y., Kishi J.-I., Hashimoto Y., Hayakawa T., Nogawa H. & Nakanishi Y.. The role of interstitial collagens in cleft formation of mouse embryonic submandibulat gland during initial branching, Development., 103, 1988, 259–267.[Abstract]
Gumbiner B.M.. Epithelial morphogenesis, Cell., 69, 1992, 385–387.[Medline]
Hiraoka N., Allen E., Apel I.J., Gyetko M.R. & Weiss S.J.. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins, Cell., 95, 1998, 365–377.[Medline]
Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S.A., Mankani M., Robey P.G., Poole A.R. & Pidoux I.. MT1-MMP–deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover, Cell., 99, 1999, 81–92.[Medline]
Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H. & Itohara S.. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice, Cancer Res., 58, 1998, 1048–1051.
Kadono Y., Shibahara K., Namiki M., Watanabe Y., Seiki M. & Sato H.. Membrane-type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in Madin-Darby canine kidney epithelial cells, Biochem. Biophys. Res. Comm., 251, 1998, 681–687.[Medline]
Knauper V., Will H., Lopez-Otin C., Smith B., Atkinson S.J., Stanton H., Hembry R.M. & Murphy G.. Cellular mechanisms for human procollagenase-3 (MMP-13) activation, J. Biol. Chem., 271, 1996, 17124–17131.
Koshikawa N., Giannelli G., Cirulli V., Miyazaki K. & Quaranta V.. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5, J. Cell Biol., 148, 2000, 615–624.
Lehti K., Lohi J., Valtanen H. & Keski-Oja J.. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface, Biochem. J., 334, 1998, 345–353.[Medline]
Lelongt B., Trugnan G., Murphy G. & Ronco P.M.. Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis, but only MMP9 is required for renal organogenesis in vitro, J. Cell Biol., 136, 1997, 1363–1373.
Liu X., Wu H., Byrne M., Jeffrey J., Krane S. & Jaenisch R.. A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling, J. Cell Biol., 130, 1995, 227–237.
Liu Z., Shipley J.M., Vu T.H., Zhou X., Diaz L.A., Werb Z. & Senior R.M.. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid, J. Exp. Med., 188, 1998, 475–482.
Llano E., Pendas A.M., Freije J.P., Nakano A., Knauper V., Murphy G. & Lopez-Otin C.. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors, Cancer Res., 59, 1999, 2570–2576.
Lochter A., Srebrow A., Sympson C.J., Terracio N., Werb Z. & Bissell M.J.. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1–dependent invasive properties, J. Biol. Chem., 272, 1997, 5007–5015a.
Lochter A., Galosy S., Muschler J., Freedman N., Werb Z. & Bissell M.J.. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells, J. Cell Biol., 139, 1997, 1861–1872b.
Mason D.P., Kenagy R.D., Hasenstab D., Bowen-Pope D.F., Siefert R.A., Coats S., Hawkins S.M. & Clowes A.W.. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery, Circ. Res., 85, 1999, 1179–1185.
Masson R., Lefebvre O., Noel A., El Fahime M., Chenard M.-P., Wendling C., Kebers F., LeMeur M., Dierich A. & Foidart J.-M.. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy, J. Cell Biol., 140, 1998, 1535–1541.
Montesano R., Schaller G. & Orci L.. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors, Cell., 66, 1991, 697–711a.[Medline]
Montesano R., Matsumoto K., Nakamura T. & Orci L.. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor, Cell., 67, 1991, 901–908b.[Medline]
Montesano R., Soriano J.V., Hosseini G., Pepper M.S. & Schramek H.. Constitutively active mitogen-activated protein kinase kinase MEK1 disrupts morphogenesis and induces an invasive phenotype in Madin-Darby canine kidney epithelial cells, Cell Growth Diff., 10, 1999, 317–332.
Mudgett J.S., Hutchinson N.I., Chartrain N.A., Forsyth A.J., McDonnell J., Singer I.I., Bayne E.K., Flanagan J., Kawka D. & Shen C.F.. Susceptibility of stromelysin-1 deficient mice to collagen-induced arthritis and cartilage destruction, Arthritis Rheum., 41, 1998, 110–121.[Medline]
Murphy G. & Gavrilovic J.. Proteolysis and cell migrationcreating a path?, Curr. Opin. Cell Biol., 11, 1999, 614–621.[Medline]
Nagase H. & Woessner J.F. Jr.. Matrix metalloproteinases, J. Biol. Chem., 274, 1999, 21491–21494.
Nakada M., Nakamura H., Ideda E., Fujimoto N., Yamashita J., Sato H., Seiki M. & Okada Y.. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors, Am. J. Pathol., 154, 1999, 417–428.
Nakahara H., Howard L., Thompson E.W., Sato H., Seiki M., Yeh Y. & Chen W.-T.. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion, Proc. Natl. Acad. Sci. USA., 94, 1997, 7959–7964.
Ohuchi E., Imai K., Fujii Y., Sato H., Seiki M. & Okada Y.. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules, J. Biol. Chem., 272, 1997, 2446–2451.
Olson M.W., Toth M., Gervasi D.C., Sado Y., Ninomiya Y. & Fridman R.. High affinity binding of latent matrix metalloproteinase-9 to the a2(IV) chain of collagen IV, J. Biol. Chem., 273, 1998, 10672–10681.
Ota K., Stetler-Stevenson W.G., Yang Q., Kumar A., Wada J., Kashihara N., Wallner E.I. & Kanway Y.S.. Cloning of murine membrane-type-1–matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor, Kidney Int., 54, 1998, 131–142.[Medline]
Parsons D.F., Marko M. & Wansor K.. Elastic reticulum and collagen of normal mouse peritoneuma conventional and high-voltage electron microscopy study, Micron., 14, 1983, 1–10.
Pei D.. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP, J. Biol. Chem., 274, 1999, 8925–8932a.
Pei D.. Leukolysin/MMP25/MT6-MMPa novel matrix metalloproteinase specifically expressed in the leukocyte lineage, Cell Research., 9, 1999, 291–303b.[Medline]
Pei D. & Weiss S.J.. Furin-dependent intracellular activation of the human stromelysin-3 zymogen, Nature., 375, 1995, 244–247.[Medline]
Pei D.Q. & Weiss S.J.. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity, J. Biol. Chem., 271, 1996, 9135–9140.
Pei D.Q., Majmudar G. & Weiss S.J.. Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3, J. Biol. Chem., 269, 1994, 25849–25855.
Polette M. & Birembaut P.. Membrane-type metalloproteinases in tumor invasion, Int. J. Biochem. Cell Biol., 30, 1998, 1195–1202.[Medline]
Pulcher B.K., Dumin J.A., Sudbeck B.D., Krane S.M., Welgus H.G. & Parks W.C.. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix, J. Cell Biol., 137, 1997, 1445–1457.
Rosenthal E.L., Johnson T.M., Allen E.D., Apel I.J., Punturieri A. & Weiss S.J.. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells, Cancer Res., 58, 1998, 521–530.
Rudolph-Owen L.A., Cannon P. & Matrisian L.M.. Overexpression of the matrix metalloproteinase matrilysin results in premature mammary gland differentiation and male infertility, Mol. Biol. Cell., 9, 1998, 421–435.
Santavicca M., Noel A., Angliker H., Stoll I., Segain J.-P., Anglard P., Chretien M., Seidah N. & Basset P.. Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases, Biochem. J., 315, 1996, 953–958.[Medline]
Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E. & Seiki M.. A matrix metalloproteinase expressed on the surface of invasive tumour cells, Nature., 370, 1994, 61–65.[Medline]
Sato H., Kinoshita T., Takino T., Nakayama K. & Seiki M.. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP-2), FEBS Lett., 393, 1996, 101–104.[Medline]
Seltzer J.L. & Eisen A.Z.. Native type I collagen is not a substrate for MMP2 (gelatinase A), J. Invest. Derm., 112, 1999, 993, .[Medline]
Shimada T., Nakamura H., Ohuchi E., Fujii Y., Murakami Y., Sato H., Seiki M. & Okada Y.. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase, Eur. J. Biochem., 262, 1999, 907–914.[Medline]
Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J.-P., Gray J.W., Pinkel D., Bissell M.J. & Werb Z.. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis, Cell., 98, 1999, 137–146.[Medline]
Sympson C.J., Talhouk R.S., Alexander C.M., Chin J.R., Clift S.M., Bissell M.J. & Werb Z.. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression, J. Cell Biol., 125, 1994, 681–693.
Tanney D.C., Feng L., Pollock A.S. & Lovett D.H.. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis, Dev. Dyn., 213, 1998, 121–129.[Medline]
Toth M., Gervasi D.C. & Fridman R.. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells, Cancer Res., 57, 1997, 3159–3167.
Ueno H., Nakamura H., Inoue M., Imai K., Noguchi M., Sato H., Seiki M. & Okada Y.. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas, Cancer Res., 57, 1997, 2055–2060.
Urena J.M., Merlos-Suarez A., Baselga J. & Arribas J.. The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF- and membrane type matrix metalloprotease (MT1-MMP), J. Cell Sci., 112, 1999, 773–784.[Abstract]
Velasco G., Cal S., Merlos-Suarez A., Ferrando A.A., Alvarez S., Nakano A, Arribas J. & Lopez-Otin C.. Human MT6-matrix metalloproteinaseidentification, progelatinase A activation, and expression in brain tumors, Cancer Res., 60, 2000, 877–882.
Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M. & Werb Z.. MMP9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes, Cell., 93, 1998, 411–422.[Medline]
Wang M., Qin X., Mudgett J.S., Ferguson T.A., Senior R.M. & Welgus H.G.. Matrix metalloproteinase deficiencies affect contact hypersensitivitystromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response, Proc. Natl. Acad. Sci. USA., 96, 1999, 6885–6889.
Weiss S.J.. Tissue destruction by human neutrophils, N. Engl. J. Med., 320, 1989, 365–376.[Medline]
Werb Z.. ECM and cell surface proteolysisregulating cellular ecology, Cell., 91, 1997, 439–442.[Medline]
Witty J.P., Wright J.H. & Matrisian L.M.. Matrix metalloproteinases are expressed during ductal and alveolar mammary morphogenesis, and misregulation of stromelysin-1 in transgenic mice induces unscheduled alveolar development, Mol. Biol. Cell., 6, 1995, 1287–1303.[Abstract]
Yana I. & Weiss S.J.. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases, Mol. Biol. Cell., In press, 2000.
Yu Q. & Stamenkovic I.. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis, Genes Dev., 14, 2000, 163–176.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
), vector control-transfected (•), full-length MT1-MMP (
), cytosolic tail-deleted MT1-MMP (MT1-MMPct; 
), and soluble MT1-MMP (
) during a 7-d culture period. Cell number at each time point was measured in triplicate and the error bars represent the SD of a single representative experiment of three performed. The inset shows Western blots of MT1-MMP expression in either control or MT-MMP transfectants as indicated. Asterisks (*) mark the position of active MT1-MMP species whereas the arrowheads mark the position of a membrane-anchored, catalytically inactive fragment of MT1-MMP (Mr 
